34795-02-3

Upstream product

• 366-18-7 [2,2]bipyridinyl 
• 14898-67-0 ruthenium trichloride hydrate 
• 10049-08-8 ruthenium(III)chloride 
• 20759-14-2 ruthenium(III) chloride hydrate 
• 68-12-2 N,N-dimethyl-formamide 
• 52389-25-0 tris(2,2’-bipyridine)ruthenium(II) 
• 55124-48-6 diazidobis(2,2'-bipyridine)ruthenium(II) 
• 14898-67-0 ruthenium(III) chloride trihydrate 
• 56-37-1 N-benzyl-N,N,N-triethylammonium chloride 
• 114397-53-4 {Ru(II)(2,2'-bipyridine)2}2(3,5-bis(pyridin-2-yl)-1,2,4-triazolate)(PF₆)3 
• 161443-89-6 trans-[Ru(2,2'-bipyridine)2(pyridine)2]⁽²⁺⁾ 
• 63358-69-0 trans-{Ru(2,2'-bipyridine)2(pyridine)2}(ClO₄)2 

Downstream Products

• 161443-91-0 {RuCl(py)(bpy)2}⁽¹⁺⁾ 
• 16887-00-6 chloride 
• 366-18-7 [2,2]bipyridinyl 
• 77321-15-4 {Ru(2,2'-bipyridine)2(2-(m-tolylazo)pyridine)}(ClO₄)2*H₂O 
• 94132-58-8 [(C₆H₅SCH₂CH₂SC₆H₅)2ClRu(C₁₀H₈N₂C₂H₂)RuCl(C₁₀H₈N₂)2]⁽²⁺⁾*2PF₆^(1-) 
• 94070-14-1 [(C₆H₅SCH₂CH₂SC₆H₅)2ClRu(C₁₀H₈N₂C₂H₄)RuCl(C₁₀H₈N₂)2]⁽²⁺⁾*2PF₆^(1-) 
• 94070-09-4 [(C₆H₅SCH₂CH₂SC₆H₅)2ClRu(C₁₀H₈N₂)RuCl(C₁₀H₈N₂)2]⁽²⁺⁾*2PF₆^(1-)=[(C₆H₅SCH₂CH₂SC₆H₅)2ClRu(C₁₀H₈N₂)RuCl(C₁₀H₈N₂)2](PF₆)2 
• 360758-38-9 [Ru(2,2'-bipyridine)2(2-(4-formylphenyl)-1H-imidazo-[4,5-f][1,10]phenanthroline)]⁽²⁺⁾ 
• 174581-95-4 Ru(C₁₀H₈N₂)2(C₆H₄OCHNC₆H₅)⁽¹⁺⁾*ClO₄^(1-)=[Ru(C₁₀H₈N₂)2(C₆H₄OCHNC₆H₅)]ClO₄ 

Relevant academic research and scientific papers

Efficient synthesis of ruthenium complexes of the type (R-bpy) 2RuCl2 and [(R-bpy)2Ru(L-L)]Cl2 by microwave-activated reactions (R: H, Me, tert-But) (L-L: Substituted bibenzimidazoles, bipyrimidine, and phenanth

Complexes of the type (R-bpy)2RuCl2 (R: H, Me, tert-but) were synthesised by microwave-activated reactions of [Ru(cod)Cl 2]n with substituted 2,2′-bipyridines in dimethylformamide in high yields and high purity.

Polynuclear heteroleptic ruthenium(II) photoredox catalysts: Evaluation in blue-light-mediated, regioselective thiol-ene reactions

Polynuclear heteroleptic ruthenium(II) photosensitisers combining either imine or amine-functionalised bipyridyl ligands were synthesised (via Schiff-base condensation/reductive amination reactions), characterised and investigated for their photoreactivity in the hydrothiolation reaction. Furthermore, electrochemical, electronic absorption and emission studies of the complexes were conducted. All the ligand-modified, heteroleptic complexes show red-shifted emission spectra (614–633 nm) relative to the canonical [Ru(bpy)3](PF6)2 complex (609 nm), attributed to the transition from the triplet MLCT excited state (3MLCT) to the ground state. The complexes were evaluated as visible-light photoredox catalysts in the radical hydrothiolation reaction of olefins (thiol-ene coupling) to afford thioethers. Control reactions performed in the absence of the photocatalyst resulted in either significantly lower yields (6%) or no product formation, demonstrating the role of the complexes as photoredox catalysts. The reactions carried out using trinuclear complexes (Ered (Ru2+*/+) = +0.300 V vs Ag/Ag+) resulted in increased yields in comparison with their respective mononuclear congeners and greater than those reported for [Ru(bpy)3](PF6)2, demonstrating the benefits of using polynuclear photocatalysts for photoinitiated redox catalysis reactions.

Physical, spectroscopic, and biological properties of ruthenium and osmium photosensitizers bearing diversely substituted 4,4′-di(styryl)-2,2′-bipyridine ligands

Capitalising on the previous identification of a distyryl coordinated Ru(ii) polypyridine complex as a promising photosensitizer for photodynamic therapy, eight new complexes were synthesized by modifications of the ligands or by changing the metal coordinated. We report in this work the effects of these modifications on the physical, spectroscopic, and biological properties of the synthesized complexes. Subtle structural modifications of the distyryl ligand only had a moderate effect on the corresponding complexes' visible light absorption and singlet oxygen quantum yield. These modifications however had a significant effect on the lipophilicity, the cellular uptake and the phototoxicity of the complexes. Although the lipophilicity of the complexes had a somewhat expected effect on their cellular uptake, this last parameter could not be directly correlated to their phototoxicity, revealing other underlying phenomena. Overall, this work allowed identification of two promising ruthenium complexes as photosensitisers for photodynamic therapy and provides some guidance on how to design better photosensitizers. This journal is

Photorelease of a metal-binding pharmacophore from a Ru(ii) polypyridine complex

The adoption of compounds that target metalloenzymes comprises a relatively low (5%) percentage of all FDA approved therapeutics. Metalloenzyme inhibitors typically coordinate to the active site metal ions and therefore contain ligands with charged or highly polar functional groups. While these groups may generate highly water-soluble compounds, this functionalization can also limit their pharmacological properties. To overcome this drawback, drug candidates can be formulated as prodrugs. While a variety of protecting groups have been developed, increasing efforts have been devoted towards the use of caging groups that can be removed upon exposure to light to provide spatial and temporal control over the treatment. Among these, the application of Ru(ii) polypyridine complexes is receiving increased attention based on their attractive biological and photophysical properties. Herein, a conjugate consisting of a metalloenzyme inhibitor and a Ru(ii) polypyridine complex as a photo-cage is presented. The conjugate was designed using density functional theory calculations and docking studies. The conjugate is stable in an aqueous solution, but irradiation of the complex with 450 nm light releases the inhibitor within several minutes. As a model system, the biochemical properties were investigated against the endonucleolytic active site of the influenza virus. While showing no inhibition in the dark in anin vitroassay, the conjugate generated inhibition upon light exposure at 450 nm, demonstrating the ability to liberate the metalloenzyme inhibitor. The presented inhibitor-Ru(ii) polypyridine conjugate is an example of computationally-guided drug design for light-activated drug release and may help reveal new avenues for the prodrugging of metalloenzyme inhibitors.

Time Resolved Ligand Loss: Flash Photolysis and UV–Vis Spectroscopic Studies of cis-[Ru(bpy)2(py)2]2+ Complex

Abstract: A preliminary study on photoinduced ligand loss from [Ru(bpy)2(py)2]2+ has been made. The photolysis of cis-[Ru(bpy)2(py)2]2+ in the presence of trifluoroacetic acid, using broad band, white light excitation, leads to a shift in λmax from 458 nm to 472 nm, consistent with a substitution reaction of the pyridine by THF. A flash photolysis study was also performed to investigate the excited state changes of [Ru(bpy)2(py)2]2+ in THF.

Ruthenium ruthenium complex as well as preparation method and pharmaceutical application thereof

The invention provides an iridium ruthenium complex and a preparation method and pharmaceutical application thereof, and belongs to the field of pharmacy. The structure of the ruthenium complex is shown in the formula I. The ruthenium complex provided by the invention can effectively inhibit breast cancer cells. A plurality of tumor cells including liver cancer cells, lung adenocarcinoma cells and esophageal cancer cells are grown. , Compound 1 is MDA-MB - 231 for breast cancer cells IC. 50 3.20 ±0.06 μm, To A549 for lung adenocarcinoma cell IC50 Low to 2.95 ±0.04 μm. The ruthenium complex provided by the invention can be used for preparing prevention and/or treatment of breast cancer. The medicine for treating various tumors such as liver cancer, lung adenocarcinoma and esophagus cancer has a wide application prospect.

Preparation method of ruthenium-based photosensitizer and application of ruthenium-based photosensitizer in photodynamic therapy of breast cancer

The invention relates to a preparation method of a ruthenium-based photosensitizer and an application thereof in photodynamic therapy of breast cancer, in particular to a ruthenium-based photosensitizer [Ru (bpy). 2 PYIP] Cl2 Preparation method and application of ruthenium complex [Ru (bpy) in photodynamic therapy of breast cancer2 PYIP] Cl2 The aqueous solution has good dispersibility, strong red fluorescence and higher singlet oxygen quantum yield under the action 640 nm laser, and can be used for photodynamic therapy of breast cancer.

Shallow Distance Dependence for Proton-Coupled Tyrosine Oxidation in Oligoproline Peptides

We have explored the kinetic effect of increasing electron transfer (ET) distance in a biomimetic, proton-coupled electron-transfer (PCET) system. Biological ET often occurs simultaneously with proton transfer (PT) in order to avoid the high-energy, charged intermediates resulting from the stepwise transfer of protons and electrons. These concerted proton-electron-transfer (CPET) reactions are implicated in numerous biological ET pathways. In many cases, PT is coupled to long-range ET. While many studies have shown that the rate of ET is sensitive to the distance between the electron donor and acceptor, extensions to biological CPET reactions are sparse. The possibility of a unique ET distance dependence for CPET reactions deserves further exploration, as this could have implications for how we understand biological ET. We therefore explored the ET distance dependence for the CPET oxidation of tyrosine in a model system. We prepared a series of metallopeptides with a tyrosine separated from a Ru(bpy)32+ complex by an oligoproline bridge of increasing length. Rate constants for intramolecular tyrosine oxidation were measured using the flash-quench transient absorption technique in aqueous solutions. The rate constants for tyrosine oxidation decreased by 125-fold with three added proline residues between tyrosine and the oxidant. By comparison, related intramolecular ET rate constants in very similar constructs were reported to decrease by 4-5 orders of magnitude over the same number of prolines. The observed shallow distance dependence for tyrosine oxidation is proposed to originate in part from the requirement for stronger oxidants, leading to a smaller hole-transfer effective tunneling barrier height. The shallow distance dependence observed here and extensions to distance-dependent CPET reactions have potential implications for long-range charge transfers.

A lysosome-targeted ruthenium(II) polypyridyl complex as photodynamic anticancer agent

Polypyridyl ruthenium complexes as novel photosensitizers had drawn attention due to its high selectivity towards cancer cells and low toxicity to normal cells. Herein, we synthesized a lysosome-targeted polypyridyl ruthenium complex Rhein-Ru(bpy)3 (bpy = 2,2′-bipyridine, rhein = 4,5-dihydroxy-9,10-dioxoanthracene-2-carboxylic acid), tethering with the Chinese medicine herb rhein. Rhein-Ru(bpy)3 exhibited high phototoxicity with short time of irradiation against tumor cell lines with the IC50 value of 2.4– 8.7 μM, and higher cytotoxicity against cisplatin-resistant A2780 cell lines, suggesting that Rhein-Ru(bpy)3 could overcome the cisplatin resistance. Moreover, Rhein-Ru(bpy)3 displayed low cytotoxicity towards cell lines in dark incubation, which was beneficial to reduce the toxic side effects towards normal cell lines. Besides, the confocal imaging and western blotting assay results suggested that Rhein-Ru(bpy)3 could induce cancer cell death through the autophagy pathway. These results inspired us that lysosome-targeted photosensitizers based on ruthenium complexes showed great potential for photodynamic therapy (PDT) application in cancer treatment.

Novel ruthenium complex as well as preparation method and application thereof in detection of 5-formylcytosine

The invention discloses a novel ruthenium complex as well as a preparation method and application thereof in detection of 5-formylcytosine. The invention provides the novel ruthenium complex and the preparation method thereof. The invention further provides a fluorescent molecular probe for detecting the 5-formylcytosine. The invention also provides a method for detecting the 5-formylcytosine by adopting the novel ruthenium complex or the ruthenium complex prepared by the preparation method or the fluorescent molecular probe. The ruthenium complex can be uniquely combined with 5fC in DNA (deoxyribonucleic acid); therefore, the 5fC in the double-stranded DNA can be specifically recognized; good fluorescence response and chemical stability are realized; the novel ruthenium complex has the advantages of good thermodynamic stability, realization of real-time detection and distribution positioning of the 5fC in the double-stranded DNA in cells, low cost, low equipment requirements, no enrichment of the 5-formylcytosine, direct detection, wide application conditions, simple and mild conditions, and high sensitivity.